Constantiam Biosciences
We are building a B2B computational platform to address the bottleneck of clinical genetic variant interpretation for actionable medical management.
- Stage Prototype Ready
- Industry Biotechnology
- Location Boston, MA, USA
- Currency USD
- Founded September 2020
- Employees 3
- Incorporation Type C-corp
- Website constantiambio.com
Company Summary
We are a B2B subscription service, and we charge an annual, per-seat license fee for use of our applications. We plan to build a stable base of clinical geneticist customers within our beachhead market of genetic testing companies. Our value proposition is to reduce the time needed for clinical geneticists to leverage valuable high-throughput functional evidence by 90%. Current practices for utilizing functional evidence are manual, and tedious.
Team
-
Co-Founder and CEO -
Co-Founder and CSO
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.